Plexus Corp. (PLXS) Reaches $65.87 52-Week High; Peak6 Investments LP Raised Its Alnylam Pharmaceuticals (Call) (ALNY) Position

January 14, 2018 - By Hazel Jackson

Peak6 Investments Lp increased Alnylam Pharmaceuticals Inc (Call) (ALNY) stake by 222.29% reported in 2017Q3 SEC filing. Peak6 Investments Lp acquired 38,900 shares as Alnylam Pharmaceuticals Inc (Call) (ALNY)’s stock rose 48.45%. The Peak6 Investments Lp holds 56,400 shares with $6.63M value, up from 17,500 last quarter. Alnylam Pharmaceuticals Inc (Call) now has $12.80B valuation. The stock increased 0.80% or $1.02 during the last trading session, reaching $129.07. About 796,481 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since January 14, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

The stock of Plexus Corp. (NASDAQ:PLXS) hit a new 52-week high and has $68.50 target or 4.00% above today’s $65.87 share price. The 9 months bullish chart indicates low risk for the $2.22 billion company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $68.50 price target is reached, the company will be worth $88.64M more. The stock increased 2.04% or $1.32 during the last trading session, reaching $65.87. About 82,898 shares traded. Plexus Corp. (NASDAQ:PLXS) has risen 19.78% since January 14, 2017 and is uptrending. It has outperformed by 3.08% the S&P500.

Analysts await Plexus Corp. (NASDAQ:PLXS) to report earnings on January, 17 after the close. They expect $0.80 EPS, down 2.44% or $0.02 from last year’s $0.82 per share. PLXS’s profit will be $26.91M for 20.58 P/E if the $0.80 EPS becomes a reality. After $0.84 actual EPS reported by Plexus Corp. for the previous quarter, Wall Street now forecasts -4.76% negative EPS growth.

Plexus Corp., together with its subsidiaries, provides electronic manufacturing services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company has market cap of $2.22 billion. It offers product conceptualization solutions; and product design and value-engineering solutions, including program management, feasibility studies, specification development for product features and functionality, circuit design, field programmable gate array design, printed circuit board layout, embedded software design, mechanical design, test specifications development and product verification testing, and automated production solutions and complex automation design. It has a 20.33 P/E ratio. The firm also provides commercialization solutions, such as prototyping, new product introduction, design for supply chain, test development, and transition management; manufacturing solutions; and fulfillment and logistics solutions.

Since August 21, 2017, it had 0 insider buys, and 2 sales for $580,598 activity. Ninivaggi Angelo Michael Jr sold 10,350 shares worth $511,898. BOER RALF R also sold $68,700 worth of Plexus Corp. (NASDAQ:PLXS) on Wednesday, August 23.

Among 11 analysts covering Plexus (NASDAQ:PLXS), 3 have Buy rating, 0 Sell and 8 Hold. Therefore 27% are positive. Plexus had 25 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Plexus Corp. (NASDAQ:PLXS) has “Buy” rating given on Thursday, October 26 by Needham. Citigroup maintained it with “Neutral” rating and $59 target in Friday, July 21 report. Citigroup maintained the stock with “Neutral” rating in Friday, October 27 report. The stock of Plexus Corp. (NASDAQ:PLXS) has “Hold” rating given on Monday, September 7 by Deutsche Bank. Goldman Sachs downgraded the shares of PLXS in report on Friday, October 23 to “Neutral” rating. As per Thursday, August 31, the company rating was maintained by RBC Capital Markets. The rating was maintained by Citigroup on Thursday, June 9 with “Neutral”. The firm has “Buy” rating given on Monday, August 3 by Goldman Sachs. As per Wednesday, November 18, the company rating was downgraded by Numis Securities. The stock has “Hold” rating by Stifel Nicolaus on Thursday, July 20.

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.10, from 1 in 2017Q2. It increased, as 18 investors sold Plexus Corp. shares while 62 reduced holdings. 30 funds opened positions while 58 raised stakes. 31.28 million shares or 0.57% more from 31.11 million shares in 2017Q2 were reported. Kennedy Capital Mgmt invested in 0.23% or 225,500 shares. Monarch Cap Mngmt holds 20,660 shares. Los Angeles Capital Mgmt And Equity Rech Inc has 67,085 shares. Profund Advsrs Lc holds 0.01% or 5,792 shares. Systematic Financial Mgmt Limited Partnership holds 29,865 shares or 0.03% of its portfolio. Geode Capital Mgmt Limited Liability Company holds 0.01% or 396,724 shares. Bowling Portfolio Limited invested in 0.09% or 10,138 shares. Lsv Asset Mngmt owns 6,200 shares. Tiaa Cref Invest Mngmt Ltd Liability owns 103,455 shares. Td Asset Management reported 12,800 shares or 0% of all its holdings. Victory Capital Mngmt Inc stated it has 389,891 shares or 0.05% of all its holdings. Swiss Savings Bank has invested 0% in Plexus Corp. (NASDAQ:PLXS). The Michigan-based Comerica Bankshares has invested 0.02% in Plexus Corp. (NASDAQ:PLXS). Pub Employees Retirement Sys Of Ohio stated it has 0.08% of its portfolio in Plexus Corp. (NASDAQ:PLXS). Great West Life Assurance Co Can holds 0.01% or 44,925 shares.

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.60, from 1.52 in 2017Q2. It dived, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Profund Lc has invested 0.15% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Highbridge Cap Management Limited Liability Company reported 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). California State Teachers Retirement Sys has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 2,725 are held by Panagora Asset Management Incorporated. Art Advisors Limited Liability Company reported 5,600 shares. Bessemer Grp reported 175 shares or 0% of all its holdings. Citigroup Incorporated stated it has 32,577 shares. Vantage Investment Advsr Ltd Limited Liability Company has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 85,000 were accumulated by Point72 Asset Management Limited Partnership. Atika Management Limited Co owns 25,000 shares. Clearbridge Lc stated it has 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Putnam Invs Ltd Llc has 0.04% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 3,485 are owned by Asset. Bancorp Of America Corp De owns 74,897 shares. Lpl Finance Limited Liability Company holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,818 shares.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 89 analyst reports since August 7, 2015 according to SRatingsIntel. JP Morgan downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, August 7. JP Morgan has “Neutral” rating and $115 target. The company was maintained on Tuesday, July 11 by Credit Suisse. The company was reinitiated on Thursday, June 22 by Jefferies. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, May 3 report. The stock has “Buy” rating by Cowen & Co on Thursday, September 21. The rating was initiated by Jefferies on Friday, October 23 with “Buy”. The firm has “Buy” rating by B. Riley & Co given on Wednesday, November 8. The rating was initiated by Nomura with “Sell” on Friday, September 15. The firm has “Mkt Perform” rating given on Thursday, October 6 by Leerink Swann. The rating was maintained by Jefferies with “Buy” on Monday, September 25.

Since September 20, 2017, it had 0 insider buys, and 3 insider sales for $23.18 million activity. Another trade for 36,745 shares valued at $4.84M was sold by Mason Michael. Greene Barry E also sold $7.68M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, September 20.

Peak6 Investments Lp decreased Unilever N V (Call) (NYSE:UN) stake by 8,800 shares to 37,300 valued at $2.20M in 2017Q3. It also reduced Hormel Foods Corp (NYSE:HRL) stake by 13,733 shares and now owns 62,567 shares. Smith A O (NYSE:AOS) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>